Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS‐CoV‐2: A Combinedin silicoandin vitroStudy
0301 basic medicine
Ritonavir
Cefotiam
SARS-CoV-2
Drug Evaluation, Preclinical
Drug Repositioning
Drugs, Investigational
Antiviral Agents
COVID-19 Drug Treatment
3. Good health
Molecular Docking Simulation
03 medical and health sciences
Spike Glycoprotein, Coronavirus
Humans
Angiotensin-Converting Enzyme 2
Coronavirus 3C Proteases
DOI:
10.1002/minf.202100062
Publication Date:
2021-09-16T12:47:03Z
AUTHORS (9)
ABSTRACT
Abstract In the current study, we used 7922 FDA approved small molecule drugs as well compounds in clinical investigation from NIH's NPC database our drug repurposing study. SARS‐CoV‐2 main protease Spike protein/ACE2 targets were virtual screening and top‐100 each docking simulations considered initially short molecular dynamics (MD) their average binding energies calculated by MM/GBSA method. Promising hit selected based on scores then long MD simulations. Based these numerical calculations following found inhibitors for protease: Pinokalant, terlakiren, ritonavir, cefotiam, telinavir, rotigaptide, cefpiramide. addition, 3 identified Spike/ACE2: Denopamine, bometolol, rotigaptide. order to verify predictions of silico analyses, 4 (ritonavir, cefpiramide) 2 (rotigaptide denopamine) Spike/ACE2 interactions tested vitro experiments. While concentration‐dependent inhibition cefotiam was observed protease; denopamine effective at binding.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....